Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - general hospital - it is indicated for use with the navi-star™ and noga-star™ catheters and the carto™ and noga™ systems to provide catheter tip location as well as electrogram information.

Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - cardiovascular - indicated for intra-cardiac and intra-luminal visualization of cardiac and great vessel anatomy and physiology as well as visualization of other devices in the heart. when used with compatible carto® ep navigation systems, the soundstar catheter provides location information.

Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - cardiovascular - indicated for catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used in conjunction with a radiofrequency generator, for cardiac ablation.

Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - cardiovascular - indicated for catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used in conjunction with a radiofrequency generator, for cardiac ablation. the thermocool™ sf nav diagnostic/ablation deflectable tip catheter provides location information when used with carto® ep navigation systems.

Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - cardiovascular - the catheter is indicated for electrophysiological mapping of cardiac structures; i.e., stimulation and recording only. in addition, the webster® duo-decapolar catheter is designed to facilitate electrogram mapping in the atrial region of the heart and the coronary sinus.

Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - cardiovascular - indicated for electrophysiological mapping of cardiac structures, i.e., stimulation and recording only.

Singapur - angličtina - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - cardiovascular - the webster® cs catheter is indicated for electrophysiological mapping of cardiac structures; i.e., stimulation and recording only. the catheter is designed for use in the coronary sinus.

Singapur - angličtina - HSA (Health Sciences Authority)

biomedix singapore pte. ltd. - immunology - reagents for the qualitative determination of anti-streptolysin o in human serum.

Singapur - angličtina - HSA (Health Sciences Authority)

kotra pharma marketing - obstetrics & gynaecology - thames bioscience sperm enhancer kit is used in sperm preparation to recover motile and viable sperms and also predict ovulation timing to carry out intrauterine insemination (iui) procedure.

Evropská unie - angličtina - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - etanercept - arthritis, rheumatoid; arthritis, juvenile rheumatoid; arthritis, psoriatic; spondylarthropathies; spondylitis, ankylosing; psoriasis - immunosuppressants - rheumatoid arthritisnepexto in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.nepexto can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. nepexto is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.nepexto, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.juvenile idiopathic arthritistreatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.etanercept has not been studied in children aged less than 2 years.psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease.axial spondyloarthritisankylosing spondylitis treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.non-radiographic axial spondyloarthritis treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).plaque psoriasistreatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-a light (puva).paediatric plaque psoriasistreatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.